Delta 9 Cannabis Past Earnings Performance
Past criteria checks 0/6
Delta 9 Cannabis's earnings have been declining at an average annual rate of -50%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 24% per year.
Key information
-50.0%
Earnings growth rate
-42.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 24.0% |
| Return on equity | n/a |
| Net Margin | -24.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Delta 9 Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 71 | -18 | 28 | 0 |
| 30 Sep 23 | 71 | -22 | 30 | 0 |
| 30 Jun 23 | 68 | -24 | 31 | 0 |
| 31 Mar 23 | 68 | -26 | 32 | 0 |
| 31 Dec 22 | 63 | -27 | 31 | 0 |
| 30 Sep 22 | 63 | -21 | 29 | 0 |
| 30 Jun 22 | 62 | -14 | 27 | 0 |
| 31 Mar 22 | 62 | -11 | 26 | 0 |
| 31 Dec 21 | 62 | -11 | 25 | 0 |
| 30 Sep 21 | 59 | -8 | 24 | 0 |
| 30 Jun 21 | 57 | -12 | 22 | 0 |
| 31 Mar 21 | 54 | -13 | 22 | 0 |
| 31 Dec 20 | 52 | -6 | 21 | 0 |
| 30 Sep 20 | 48 | -8 | 18 | 0 |
| 30 Jun 20 | 42 | -4 | 18 | 0 |
| 31 Mar 20 | 38 | -3 | 17 | 0 |
| 31 Dec 19 | 32 | 11 | 17 | 0 |
| 30 Sep 19 | 26 | 12 | 19 | 0 |
| 30 Jun 19 | 21 | 11 | 19 | 0 |
| 31 Mar 19 | 13 | 10 | 17 | 0 |
| 31 Dec 18 | 8 | -8 | 14 | 0 |
| 30 Sep 18 | 3 | -12 | 10 | 0 |
| 30 Jun 18 | 2 | -11 | 7 | 0 |
| 31 Mar 18 | 1 | -9 | 5 | 0 |
| 31 Dec 17 | 1 | -8 | 3 | 0 |
| 30 Sep 17 | 1 | -2 | 2 | 0 |
| 30 Jun 17 | 1 | -2 | 2 | 0 |
| 31 Mar 17 | 1 | -1 | 2 | 0 |
| 31 Dec 16 | 0 | -1 | 2 | 0 |
| 31 Dec 15 | 1 | -1 | 1 | 0 |
Quality Earnings: V5D1 is currently unprofitable.
Growing Profit Margin: V5D1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: V5D1 is unprofitable, and losses have increased over the past 5 years at a rate of 50% per year.
Accelerating Growth: Unable to compare V5D1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: V5D1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: V5D1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.